Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist that has gained popularity for its effectiveness in managing type 2 diabetes and obesity, becoming one of the top treatments according to different diabetes guidelines [1]. The gene discussed is GCG; the disease is obesity due to melanocortin 4 receptor deficiency.